chevrons

Back to Previous Page

Company Quarterly Earnings Update – IMP VN – 2019 Q1

Summary of the Q1/2019 results of Imexpharm Pharma. JSC (IMP VN) 

Q1/2019 results: highlights
  • Revenue was VND 273 bn, +7.9% yoy. Revenue from own products, and outsourced products accounted for 91.0% and for 8.5% of that amount, respectively. Within the own product segment, sales through hospitals registered  strong growth of 18.2%, while sales  through pharmacies were up by 8.2%.
  • The company’s gross margin rose However, IMP was affected  by  higher operating expenses, mostly for marketing activities, partly offsetting the improved gross margin. The bottom line recorded VND 36 bn, +10.5% yoy.
  • IMP’s financial position remained solid with negligible borrowing.
  • The AGM approved a dividend of VND2,000/share for the 2018FY.
Outlook
  • FitchSolutions (previously BMI) forecasts an 11.0% CAGR from now till 2027 for pharmaceutical sales in local currency. The segment of prescribed medicine is estimated to grow faster and to contribute 77% of the whole market by 2027, up from 75% in 2018, mainly thanks to  increased insurance coverage. It seems that the market currently prefers  imported medicine (56% of total medicine) for quality reason. However, new regulations are supporting domestic firms, which can produce high-quality drugs that are compliant with international
  • We estimate IMP to grow faster than the industry average, with a 17.4% CAGR for own product revenue till 2023, thanks to added capacity with GMP-EU standards. The extra capacity will allow IMP to sell more products to public hospitals. Please note that, in 2018, IMP accounted for only ~2% of all domestic producers’ revenue.
  • IMP’s bottom line is set to grow at a similar pace: 17.0% CAGR till 2023.

 

Recommendation

Company ratings and target prices are accessible for clients only.

If you are interested in getting full access to our paid Primary Research Materials feel free to get in touch with us at your convenience.

Our team is actively covering 50 companies in the listed Vietnamese equity space for our clients.


Featured image credit: vccinews.com

Related News & Insights
Find out more navigation_button
news

Summary of Q1 2026 results and outlook of Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD VN) Net revenue rose 1.6% y/y to VND448bn. Growth was led by kidney dialysis products (+11.8% y/y), minerals, vitamins & supplements (+29.4% y/y), and psychiatric & neurological disorder therapies (+20.5% y/y). Oncology products (+1.5% y/y) and antibiotics (-15.2% y/y) […]

Read Newsarrow
news

Summary of Q1 2026 results and outlook of Nam Long Investment (NLG VN) The real estate market continued to record an increase in new supply, supported by the ongoing easing of legal procedures. However, supply-demand imbalances persist in major cities, where new launches remain concentrated in the high-end and luxury segments. On the demand side, […]

Read Newsarrow
news

Summary of Q1 2026 results and outlook of Phuoc Hoa Rubber JSC (PHR VN) PHR operates two core business lines: (1) rubber plantation and natural rubber sales, and (2) the conversion of plantation land for IP development. Net profit increased 177.4% y/y to VND285bn, mainly driven by the IP segment, where profit rose 4.9x y/y […]

Read Newsarrow
Find out more navigation_button